Kevin Patrick Danahy - 14 Feb 2022 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role: Chief Commercial Office
Signature: /s/ Kenneth B. Stratton, as Attorney-in-Fact
Issuer symbol: PLSE
Transactions as of: 14 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 22 Mar 2022, 16:11:33 UTC
Next filing: 24 Mar 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PLSE	Stock Option (right to buy)	Award		+300,000			300,000	14 Feb 2022	Common Stock	300,000	$6.41	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option was granted on February 14, 2022 under the Issuer's 2017 Inducement Equity Incentive Plan. The shares subject to the option are subject to a mix of time-based and performance-based vesting criteria. 200,000 shares will vest in equal annual installments over the following four years on the anniversary of the grant date and 100,000 shares will vest in two equal annual installments on the third and fourth anniversaries of the grant date, in all cases, subject to the Reporting Person's continued service through each vesting date.
F2	Not applicable.

Content

The option was granted on February 14, 2022 under the Issuer's 2017 Inducement Equity Incentive Plan. The shares subject to the option are subject to a mix of time-based and performance-based vesting criteria. 200,000 shares will vest in equal annual installments over the following four years on the anniversary of the grant date and 100,000 shares will vest in two equal annual installments on the third and fourth anniversaries of the grant date, in all cases, subject to the Reporting Person's continued service through each vesting date.

Not applicable.